A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
Key facts
- Who runs it
- Assembly Biosciences
- Where
- Kansas City, Rochester, and Seattle, United StatesSee the 4 sitesAlso in 2 other countries, 14 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 103 people enrolled
- Started
- 8 Dec 2024
- Ended
- 19 Jan 2026
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ABI-1179
- ABI-1179 Placebo
- Record updated
- 23 March 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Other criteria
- Part A: Inclusion Criteria:
- Subject has a body mass index (BMI) between ≥18.0 and <32.0 kg/m2
- In good health (as determined by the Investigator) based on medical history, physical examination, ECG, and clinical laboratory results
- Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day-1 or Day 1 (predose)
- Agreement to comply with protocol-specified contraceptive requirements; Part B: Inclusion Criteria:
- Subject has a body mass index (BMI) between ≥18.0 and <32.0 kg/m2
- Other than HSV infection, is in good health (as determined by the investigator) based on medical history, physical examination, ECG, and clinical laboratory results
- Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day 1 (predose)
- Agreement to comply with protocol-specified contraceptive requirements; Part A and B: Exclusion Criteria:
- Current infection of human immunodeficiency virus (HIV), hepatitis B virus, (HBV), hepatitis C virus (HCV), acute hepatitis A virus (HAV), or acute hepatitis E virus (HEV)
- History of any illness that, in the opinion of the Investigator, might confound the results of the study, pose an additional risk in administering study drug to the subject, or condition known to interfere with the absorption /distribution/ elimination of drugs
- History of any significant drug-related allergic reactions such as anaphylaxis, Stevens-Johnson Syndrome, urticaria, or multiple drug allergies
- History of persistent alcohol abuse or illicit drug abuse within 3 years prior to screening
- Has participated in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 half-lives before screening, whatever is longer
Where in United States
Also in 2 other countries, 14 sites
- Alliance for Multispecialty ResearchKansas City, United States
- Rochester Clinical ResearchRochester, United States
- Seattle Clinical Research CenterSeattle, United States
- University of Washington Virology Research ClinicSeattle, United States
About the trial
What the trial wants to find out
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A.
The 5 groups in the trial
- Part A: SAD Cohorts 1-5, ABI-1179Treatment being tested
Single dose of ABI-1179 (tablet) in Part A for cohorts 1-5
Treatment: ABI-1179 and ABI-1179 Placebo
- Part A:SAD Cohorts 1-5, PlaceboPlacebo, for comparison
Single dose of matching placebo (tablet) in Part A for Cohorts 1-5
Treatment: ABI-1179 and ABI-1179 Placebo
- Part A: (SAD) Fed Cohort 6 or 7, ABI-1179Treatment being tested
Single dose of ABI-1179 (tablet) in Part A for Cohort 6 or 7, food effect
Treatment: ABI-1179 and ABI-1179 Placebo
- Part B: MAD Cohorts 1-4, ABI-1179Treatment being tested
Weekly dose ofABI-1179 (tablet) in Part B for Cohorts 1-4. May have loading dose.
Treatment: ABI-1179 and ABI-1179 Placebo
- Part B: MAD Cohorts 1-4 PlaceboPlacebo, for comparison
Weekly dose of matching placebo (tablet) in Part B for Cohorts 1-4.
Treatment: ABI-1179 and ABI-1179 Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple Ascending Doses of ABI-1179 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes
- Record updated
- 23 March 2026